30 results on '"Sun, Xiao-Feng"'
Search Results
2. Loss of cancer cell‐derived ADAM15 alters the tumor microenvironment in colorectal tumors.
- Author
-
Puig‐Blasco, Laia, Piotrowski, Krzysztof B., Michaelsen, Signe R., Bager, Nicolai S., Areškevičiūtiė, Aušrinė, Thorseth, Marie‐Louise, Sun, Xiao‐Feng, Keller, Ulrich auf dem, Kristensen, Bjarne W., Madsen, Daniel H., Gnosa, Sebastian P., and Kveiborg, Marie
- Subjects
COLON tumors ,TUMOR microenvironment ,CANCER cells ,SUBCUTANEOUS injections ,COLON cancer ,RECTAL cancer - Abstract
Tumor progression and response to treatment are highly affected by interactions between cancer cells and the tumor microenvironment (TME). Many of the soluble factors and signaling receptors involved in this crosstalk are shed by a disintegrin and metalloproteinases (ADAMs). Upregulation of ADAM15 has been linked to worse survival in cancer patients and a tumor‐promoting function both in vitro and in murine cancer models. Although ADAM15 has been involved in cell‐cell and cell‐extracellular matrix interactions, its role in the crosstalk between cancer cells and the TME in vivo remains unexplored. Therefore, we aimed to understand how ADAM15 regulates the cell composition of the TME and how it affects tumor progression. Here, we showed an upregulation of ADAM15 in tumor tissues from rectal cancer patients. Subcutaneous injection of wildtype and ADAM15‐knockout CT26 colon cancer cells in syngeneic mice confirmed the protumorigenic role of ADAM15. Profiling of tumors revealed higher immune cell infiltration and cancer cell apoptosis in the ADAM15‐deficient tumors. Specifically, loss of ADAM15 led to a reduced number of granulocytes and higher infiltration of antigen‐presenting cells, including dendritic cells and macrophages, as well as more T cells. Using in vitro assays, we confirmed the regulatory effect of ADAM15 on macrophage migration and identified ADAM15‐derived CYR61 as a potential molecular mediator of this effect. Based on these findings, we speculate that targeting ADAM15 could increase the infiltration of immune cells in colorectal tumors, which is a prerequisite for effective immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Wavelet scattering networks in deep learning for discovering protein markers in a cohort of Swedish rectal cancer patients.
- Author
-
Pham, Tuan D. and Sun, Xiao‐Feng
- Subjects
- *
RECTAL cancer , *SIGNAL convolution , *DEEP learning , *RECEIVER operating characteristic curves , *CANCER patients , *CONVOLUTIONAL neural networks , *TUMOR markers - Abstract
Background: Cancer biomarkers play a pivotal role in the diagnosis, prognosis, and treatment response prediction of the disease. In this study, we analyzed the expression levels of RhoB and DNp73 proteins in rectal cancer, as captured in immunohistochemical images, to predict the 5‐year survival time of two patient groups: one with preoperative radiotherapy and one without. Methods: The utilization of deep convolutional neural networks in medical research, particularly in clinical cancer studies, has been gaining substantial attention. This success primarily stems from their ability to extract intricate image features that prove invaluable in machine learning. Another innovative method for extracting features at multiple levels is the wavelet‐scattering network. Our study combines the strengths of these two convolution‐based approaches to robustly extract image features related to protein expression. Results: The efficacy of our approach was evaluated across various tissue types, including tumor, biopsy, metastasis, and adjacent normal tissue. Statistical assessments demonstrated exceptional performance across a range of metrics, including prediction accuracy, classification accuracy, precision, and the area under the receiver operating characteristic curve. Conclusion: These results underscore the potential of dual convolutional learning to assist clinical researchers in the timely validation and discovery of cancer biomarkers. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. The impact of adjuvant chemotherapy on survival in mucinous and non-mucinous rectal adenocarcinoma patients after TME surgery.
- Author
-
Vernmark, Karolina, Knutsen, Annika, Loftås, Per, and Sun, Xiao-Feng
- Subjects
ADJUVANT chemotherapy ,NEOADJUVANT chemotherapy ,MUCINOUS adenocarcinoma ,CANCER chemotherapy ,RECTAL cancer ,OLDER patients - Abstract
Introduction: The value of adjuvant chemotherapy for rectal cancer patients is debated and varies in different subgroups. One such subgroup is mucinous adenocarcinoma (MAC), which is more treatment resistant compared to non-mucinous adenocarcinoma (NMAC). To date, mucinous histology is not taken into account when deciding on adjuvant treatment strategy. This is the first study to exclusively include patients with rectal cancer, then separate MAC and NMAC and compare the survival in patients that had or did not have adjuvant chemotherapy. Material and methods: The study included retrospective register data from 365 Swedish patients with stage II-IV rectal adenocarcinoma, 56 patients with MAC and 309 patients with NMAC. All patients were considered curative, had surgery with total mesorectal excision in 2004–2013, and were followed up until death or 2021. Results: Patients with MAC that had adjuvant chemotherapy had better overall survival (OS, HR 0.42; CI 95%: 0.19–0.93; p = 0.032) and a trend towards better cancer-specific survival (CSS, HR 0.41 CI 95%: 0.17–1.03; p = 0.057) compared to patients without chemotherapy (HR 0.42; CI 95%: 0.19–0.93; p = 0.032). The difference in OS was still significant even after adjusting for sex, age, stage, differentiation, neoadjuvant chemotherapy and preoperative radiotherapy (HR 0.40; CI 95%: 0.17–0.92; p = 0.031). There was no such difference in the NMAC patients except in the stage-by-stage subgroup analyses where patients in stage IV had better survival after adjuvant chemotherapy. Conclusions: There may be a difference in treatment response to adjuvant chemotherapy between MAC and NMAC patients. Patients with MAC could possibly benefit from adjuvant chemotherapy in stages II-IV. Further studies are however needed to confirm these results. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. A clinical study of metastasized rectal cancer treatment: assessing a multimodal approach
- Author
-
Jung, Michaela, Holmqvist, Annica, Sun, Xiao-Feng, and Albertsson, Maria
- Published
- 2014
- Full Text
- View/download PDF
6. Mucinous and Non-Mucinous Rectal Adenocarcinoma—Differences in Treatment Response to Preoperative Radiotherapy
- Author
-
Vernmark, Karolina, Sun, Xiao-Feng, and Holmqvist, Annica
- Subjects
mucinous adenocarcinoma ,non-mucinous adenocarcinoma ,radiotherapy ,rectal cancer ,survival ,Cancer och onkologi ,Cancer and Oncology ,lcsh:R ,lcsh:Medicine ,Article - Abstract
There is a need to personalize the treatment for rectal cancer patients. The aim of this study was to analyze therapy response and prognosis after preoperative radiotherapy in rectal cancer patients with mucinous adenocarcinoma compared to those with non-mucinous adenocarcinoma. The study included retrospectively collected data from 433 patients, diagnosed with rectal cancer in the South East health care region in Sweden between 2004 and 2012. Patients with non-mucinous adenocarcinoma that received short-course radiotherapy before surgery had better overall survival, cancer specific survival, and disease-free survival, as well as distant- and local-recurrence-free survival (p = 0.003, p = 0.001, p = 0.002, p = 0.002, and p = 0.033, respectively) compared to the patients that received long-course radiotherapy with concomitant capecitabine. The results were still significant after adjusting for sex, age, stage, differentiation, and chemotherapy in the neoadjuvant and/or adjuvant setting, except for local-recurrence-free survival that was trending towards significance (p = 0.070). In patients with mucinous adenocarcinoma, no difference in survival was seen when comparing patients that had short-course radiotherapy and patients that had long-course radiotherapy. However, none of 18 patients with mucinous adenocarcinoma treated with long-course radiotherapy had local tumor progression, compared to 7% of 67 patients with non-mucinous adenocarcinoma. The results indicate that mucinous adenocarcinoma and non-mucinous adenocarcinoma may respond differently to radiotherapy. Funding Agencies|Swedish Cancer Foundation [CAN 2016/341]; Liu Cancer Network [200331]; Foundation of the Department in Oncology in Linkopings Research Fund [06000896]; Region Ostergotland, Sweden [06000933]
- Published
- 2020
7. pRb2/p130 protein in relation to clinicopathological and biological variables in rectal cancers with a clinical trial of preoperative radiotherapy
- Author
-
Moparthi, Satish Babu, Bergman, Viveka, Adell, Gunnar, Thorstensson, Sten, and Sun, Xiao-Feng
- Published
- 2009
- Full Text
- View/download PDF
8. Predictive Role of Biopsy Based Biomarkers for Radiotherapy Treatment in Rectal Cancer
- Author
-
Wen, Yugang, Zhao, Senlin, Holmqvist, Annica, Hahn-Stromberg, Victoria, Adell, Gunnar, Holmlund, Birgitta, Pathak, Surajit, Peng, Zhihai, and Sun, Xiao-Feng
- Subjects
Cancer och onkologi ,biomarker ,biopsy ,radiotherapy ,rectal cancer ,prognosis ,Cancer and Oncology ,lcsh:R ,lcsh:Medicine ,food and beverages ,Article - Abstract
Background and Purpose: Radiation therapy has long been contemplated as an important mode in the treatment of rectal cancer. However, there are few ideal tools available for clinicians to make a radiotherapy decision at the time of diagnosis for rectal cancer. The purpose of this study was to assess whether biomarkers expressed in the biopsy could help to choose the suitable therapy and provide predictive and/or prognostic information. Experimental Design: In total, 30 biomarkers were analyzed in 219 biopsy samples before treatment to discover the possibility of using them as an indicator for radiotherapy selection, diagnosis, survival and recurrence. Results: Twenty-two biomarkers (COX2-RT, COX2-NonRT, etc.; 36.67%) had diagnostic value. For survival, four biomarkers (NFKBP65, p130, PINCH and PPAR) were significant in regulating gene promoter activity and overall survival, while four had a trend (AEG1, LOX, SATB1 and SIRT6). Three biomarkers (COX2, PINCH and WRAP53) correlated with disease-free survival, while eight had a trend (AEG1, COX2, Ki67, LOX, NFKBP65, PPAR and SATB1). Four biomarkers (COX2-RT, NFKBP65cyto-RT, P130cyto-NonRT and PPARcyto-RT) were independent prognostic factors for recurrence. NFKBP65 and SIRT6 were significantly correlated with lymph node metastasis regardless of radiation. Patients with high AEG1, LOX, NFKBP65, PPAR and SATB1 had or showed a positive trend for better survival after radiotherapy, while those with positive PINCH and WRAP53 expression would not benefit from radiotherapy. Conclusions: AEG1, LOX, NFKBP65cyto, PPAR and SATB1 could be used as indicators for choosing radiotherapy. COX2-RT, COX2-NonRT and some other biomarkers may provide additional help for diagnosis. Funding Agencies|Shanghai Science and Technology CommitteeShanghai Science & Technology Committee [17ZR1422800]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81972215]; Swedish Cancer Foundation; Swedish Research CouncilSwedish Research Council; Health Research Council in South-East Sweden
- Published
- 2020
9. Expressions of miR-302a, miR-105, and miR-888 Play Critical Roles in Pathogenesis, Radiotherapy, and Prognosis on Rectal Cancer Patients : A Study From Rectal Cancer Patients in a Swedish Rectal Cancer Trial of Preoperative Radiotherapy to Big Database Analyses
- Author
-
Meng, Wen-Jian, Pathak, Surajit, Zhang, Xueli, Adell, Gunnar, Jarlsfelt, Ingvar, Holmlund, Birgitta, Wang, Zi-Qiang, Zhang, Alexander S., Zhang, Hong, Zhou, Zong-Guang, and Sun, Xiao-Feng
- Subjects
Cancer och onkologi ,Cancer and Oncology ,miRNAs ,pathogenesis ,radiotherapy ,prognosis ,rectal cancer - Abstract
Differential expressions and functions of various micoRNAs (miRNAs) have been intensively studied in both colon and rectal cancers. However, the importance of miRNAs on radiotherapy (RT) response and clinical outcome in rectal cancer patients remains unclear. In this study, we used real-time polymerase chain reaction to examine the expressions of miR-302a, miR-105, and miR-888 in normal mucosa and cancer tissue from rectal cancer patients with and without preoperative RT. The biological function of miR-302a, miR-105, and miR-888 expression was further analyzed and identified through the public databases: TCGA (The Cancer Genome Atlas) and GEPIA (Gene Expression Profiling Interactive Analysis). The results showed that the expression of miR-105 in rectal cancer was higher than that in normal mucosa in RT (P= 0.042) and non-RT patients (P= 0.003) and was associated with mucinous histological type (P= 0.004), COX-2 (P= 0.042), and p73 expression (P= 0.030). The expression of miR-302a was shown more frequently in cancers with necrosis (P= 0.033) and with WRAP53 expression (P= 0.015), whereas miR-888 expression occurred more frequently in tumors with protein the expression of survivin (P= 0.015), AEG-1 (astrocyte elevated gene-1) (P= 0.003), and SATB1 (special AT-rich sequence binding protein 1) (P= 0.036). Moreover, TargetScan also predicted AEG-1 and SATB1 as putative targets for miR-888. The miRNA-gene network analysis showed that ABI2 was associated with all the three miRNAs, with lower expression and good diagnostic value in rectal cancers. The TCGA database demonstrated the association of miR-105 expression with high carcinoembryonic antigen level (P= 0.048). RT reduced the expressions of miR-302a, miR-105, and miR-888. Prognostic analysis showed that miR-888 expression was independently associated with worse survival of patients without RT [overall survival,P= 0.001; disease-free survival,P= 0.009]. Analysis of biological function revealed that the protein serine/threonine kinase activity and PI3K-AKT signaling pathway were the most significantly enriched functions and pathways, respectively. Our findings suggest that miR-105 is involved in rectal cancer pathogenesis and miR-888 is associated with prognosis. MiR-302a, miR-105, and miR-888 have potential influence on the pathogenesis, RT, and prognosis of rectal cancer. Funding Agencies|Swedish Cancer Foundation; Swedish Research CouncilSwedish Research Council; Health Research Council in the South-East of Sweden [1921-B91-08XBC]
- Published
- 2020
10. Prognostic value of nuclear FBI-1 in patients with rectal cancer with or without preoperative radiotherapy
- Author
-
Wang, Chaojie, Chao, Chu-Rui, Liu, Hui-Min, Zhu, Yan-Yan, Adell, Gunnar, Jarlsfelt, Ingvar, Zhang, Hong, and Sun, Xiao-Feng
- Subjects
Cancer och onkologi ,factor that binds to the inducer of short transcripts of the human immunodeficiency virus-1 ,rectal cancer ,prognosis ,preoperative radiotherapy ,biomarker ,Cancer and Oncology - Abstract
Factor that binds to the inducer of short transcripts of the human immunodeficiency virus-1 (FBI-1) represents as a crucial gene regulator in colorectal cancer; however, the correlation between FBI-1 and preoperative radiotherapy (RT) in rectal cancer (RC) has not yet been reported. The aim was to detect FBI-1 expression in patients with RC with or without RT, by immunohistochemistry and quantitative polymerase chain reaction, and to analyze its association with clinicopathological features and response to RT. The results from immunohistochemistry analysis (n=139) and reverse transcription-quantitative polymerase chain reaction (n=55) demonstrated that FBI-1 was overexpressed in patients with RC, whether they had received preoperative RT or not. Subsequently, the association between FBI-1 expression, and the clinicopathological features and response to RT in patients with RC was analyzed. Cytoplasmic FBI-1 was upregulated in non-RT (n=77) and RT (n=62) groups (17.7 vs. 74.0%, Pamp;lt;0.001; 41.1 vs. 69.4%, P=0.002, respectively) of patients with RC compared with normal mucosa. However, nuclear FBI-1 was downregulated (75.8 vs. 22.1%, Pamp;lt;0.001; 83.9 vs. 35.5%, Pamp;lt;0.001, respectively) in both groups. RT had no significant effect on FBI-1 expression in RC tissues. Furthermore, nuclear FBI-1 was positively associated with tumor-node-metastasis stage and distant recurrence (P=0.003 and P=0.010, respectively). In patients with stage I, II or III RC, higher nuclear FBI-1 expression was associated with poorer disease-free survival [hazard ratio (HR)=1.934, 95% confidence interval (CI): 1.055-3.579, P=0.033] and overall survival (HR=2.174, 95% CI: 1.102-4.290, P=0.025), independently of sex, age, growth pattern, differentiation and RT. In addition, FBI-1 was positively correlated with numerous biological factors, including p73 [Spearmans correlation coefficient (r(s))=0.332, P=0.007], lysyl oxidase (r(s)=0.234, P=0.043), Wrap53 (r(s)=-0.425, P=0.0002) and peroxisome proliferator-activated receptor delta (r(s)=-0.294, P=0.026). In conclusion, the present study demonstrated that nuclear FBI-1 was an independent prognostic factor in patients with RC and correlated with numerous biological factors, which indicated that it may have multiple roles in RC. Funding Agencies|National Natural Science Foundation of ChinaNational Natural Science Foundation of China [U1204818]; Projects of Science and Technology in Henan Province [172102310064, 201702195]; Swedish Cancer Foundation [3610-B06-11XCC]
- Published
- 2019
11. WRAP53 is an independent prognostic factor in rectal cancer- a study of Swedish clinical trial of preoperative radiotherapy in rectal cancer patients
- Author
-
Zhang Hong, Wang Da-Wei, Adell Gunnar, and Sun Xiao-Feng
- Subjects
WRAP53 ,Radiotherapy ,Prognosis ,Rectal cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Expression of WRAP53 protein has oncogenic properties and it is up regulated in several types of tumors. Methods We examined expression of WRAP53 protein in rectal cancers and analyzed its relationship to the response to preoperative radiotherapy and patient survival. The WRAP53 protein was examined by immunohistochemistry in normal mucosa, primary tumors and lymph node metastases from 143 rectal cancer patients participated in a Swedish clinical trial of preoperative radiotherapy. Results Frequency of WRAP53 protein expression was increased in primary rectal cancer compared to the normal mucosa (p Conclusion WRAP53 may be a new biomarker used to predict prognosis and to select suitable patients for preoperative radiotherapy.
- Published
- 2012
- Full Text
- View/download PDF
12. PINCH is an independent prognostic factor in rectal cancer patients without preoperative radiotherapy - a study in a Swedish rectal cancer trial of preoperative radiotherapy
- Author
-
Holmqvist Annica, Gao Jingfang, Holmlund Birgitta, Adell Gunnar, Carstensen John, Langford Dianne, and Sun Xiao-Feng
- Subjects
PINCH ,Radiotherapy ,Prognosis ,Rectal cancer ,Immunohistochemistry ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background The clinical significance between particularly interesting new cysteine-histidine rich protein (PINCH) expression and radiotherapy (RT) in tumours is not known. In this study, the expression of PINCH and its relationship to RT, clinical, pathological and biological factors were studied in rectal cancer patients. Methods PINCH expression determined by immunohistochemistry was analysed at the invasive margin and inner tumour area in 137 primary rectal adenocarcinomas (72 cases without RT and 65 cases with RT). PINCH expression in colon fibroblast cell line (CCD-18 Co) was determined by western blot. Results In patients without RT, strong PINCH expression at the invasive margin of primary tumours was related to worse survival, compared to patients with weak expression, independent of TNM stage and differentiation (P = 0.03). No survival relationship in patients with RT was observed (P = 0.64). Comparing the non-RT with RT subgroup, there was no difference in PINCH expression in primary tumours (invasive margin (P = 0.68)/inner tumour area (P = 0.49). In patients with RT, strong PINCH expression was related to a higher grade of LVD (lymphatic vessel density) (P = 0.01) Conclusions PINCH expression at the invasive margin was an independent prognostic factor in patients without RT. RT does not seem to directly affect the PINCH expression.
- Published
- 2012
- Full Text
- View/download PDF
13. Prognostic Heterogeneity of MRE11 Based on the Location of Primary Colorectal Cancer Is Caused by Activation of Different Immune Signals.
- Author
-
Fan, Chuan-Wen, Kopsida, Maria, Liu, You-Bin, Zhang, Hong, Gao, Jing-Fang, Arbman, Gunnar, Cao, Si-Yu-Wei, Li, Yuan, Zhou, Zong-Guang, and Sun, Xiao-Feng
- Subjects
COLORECTAL cancer ,ETIOLOGY of cancer ,RECTAL cancer ,TUMOR classification ,DNA repair ,NECROSIS - Abstract
Background: MRE11 plays an important role in DNA damage response for the maintenance of genome stability, and is becoming a prognostic marker for cancers, including colorectal cancer (CRC). However, the correlations of MRE11 to prognosis and tumor-infiltrating inflammatory cells (TIICs) in different locations of CRC remains unclear. Methods: Among Swedish and TCGA-COREAD patients, we investigated the association of MRE11 expression, tumor-infiltrating inflammatory cells (TIICs) and microsatellite status with survival in right-sided colon cancer (RSCC) and left-sided colon and rectal cancer (LSCRC). The signaling of MRE11-related was further analyzed using weighted gene co-expression network analysis and ClueGO. Results: High MRE11 expression alone or combination of high MRE11 expression with high TIICs was related to favorable prognosis in LSCRC. Moreover, high MRE11 expression was associated with favorable prognosis in LSCRC with microsatellite stability. The relationships above were adjusted for tumor stage, differentiation, and/or TIICs. However, no such evidence was observed in RSCC. Several signaling pathways involving MRE11 were found to be associated with cell cycle and DNA repair in RSCC and LSCRC, whereas, the activation of the immune response and necrotic cell death were specifically correlated with LSCRC. Conclusions: High MRE11 expression is an independent prognostic marker in LSCRC and enhanced prognostic potency of combining high MRE11 with high TIICs in LSCRC, mainly due to differential immune signaling activated by MRE11 in RSCC and LSCRC, respectively. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
14. Image-Based Network Analysis of DNp73 Expression by Immunohistochemistry in Rectal Cancer Patients.
- Author
-
Pham, Tuan D., Fan, Chuanwen, Pfeifer, Daniella, Zhang, Hong, and Sun, Xiao-Feng
- Subjects
RECTAL cancer ,CANCER patients ,TUMOR classification ,IMMUNOHISTOCHEMISTRY ,TUMOR proteins ,COLON cancer - Abstract
Background: Rectal cancer is a disease characterized with tumor heterogeneity. The combination of surgery, radiotherapy, and chemotherapy can reduce the risk of local recurrence. However, there is a significant difference in the response to radiotherapy among rectal cancer patients even they have the same tumor stage. Despite rapid advances in knowledge of cellular functions affecting radiosensitivity, there is still a lack of predictive factors for local recurrence and normal tissue damage. The tumor protein DNp73 is thought as a biomarker in colorectal cancer, but its clinical significance is still not sufficiently investigated, mainly due to the limitation of human-based pathology analysis. In this study, we investigated the predictive value of DNp73 in patients with rectal adenocarcinoma using image-based network analysis. Methods: The fuzzy weighted recurrence network of time series was extended to handle multi-channel image data, and applied to the analysis of immunohistochemistry images of DNp73 expression obtained from a cohort of 25 rectal cancer patients who underwent radiotherapy before surgery. Two mathematical weighted network properties, which are the clustering coefficient and characteristic path length, were computed for the image-based networks of the primary tumor (obtained after operation) and biopsy (obtained before operation) of each cancer patient. Results: The ratios of two weighted recurrence network properties of the primary tumors to biopsies reveal the correlation of DNp73 expression and long survival time, and discover the non-effective radiotherapy to a cohort of rectal cancer patients who had short survival time. Conclusion: Our work contributes to the elucidation of the predictive value of DNp73 expression in rectal cancer patients who were given preoperative radiotherapy. Mathematical properties of fuzzy weighted recurrence networks of immunohistochemistry images are not only able to show the predictive factor of DNp73 expression in the patients, but also reveal the identification of non-effective application of radiotherapy to those who had poor overall survival outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
15. Prognostic value of nuclear FBI-1 in patients with rectal cancer with or without preoperative radiotherapy.
- Author
-
Wang, Chao-Jie, Chao, Chu-Rui, Liu, Hui-Min, Zhu, Yan-Yan, Adell, Gunnar, Jarlsfelt, Ingvar, Zhang, Hong, and Sun, Xiao-Feng
- Subjects
RECTAL cancer ,PEROXISOME proliferator-activated receptors ,LYSYL oxidase ,REGULATOR genes ,POLYMERASE chain reaction - Abstract
Factor that binds to the inducer of short transcripts of the human immunodeficiency virus-1 (FBI-1) represents as a crucial gene regulator in colorectal cancer; however, the correlation between FBI-1 and preoperative radiotherapy (RT) in rectal cancer (RC) has not yet been reported. The aim was to detect FBI-1 expression in patients with RC with or without RT, by immunohistochemistry and quantitative polymerase chain reaction, and to analyze its association with clinicopathological features and response to RT. The results from immunohistochemistry analysis (n=139) and reverse transcription-quantitative polymerase chain reaction (n=55) demonstrated that FBI-1 was overexpressed in patients with RC, whether they had received preoperative RT or not. Subsequently, the association between FBI-1 expression, and the clinicopathological features and response to RT in patients with RC was analyzed. Cytoplasmic FBI-1 was upregulated in non-RT (n=77) and RT (n=62) groups (17.7 vs. 74.0%, P<0.001; 41.1 vs. 69.4%, P=0.002, respectively) of patients with RC compared with normal mucosa. However, nuclear FBI-1 was downregulated (75.8 vs. 22.1%, P<0.001; 83.9 vs. 35.5%, P<0.001, respectively) in both groups. RT had no significant effect on FBI-1 expression in RC tissues. Furthermore, nuclear FBI-1 was positively associated with tumor-node-metastasis stage and distant recurrence (P=0.003 and P=0.010, respectively). In patients with stage I, II or III RC, higher nuclear FBI-1 expression was associated with poorer disease-free survival [hazard ratio (HR)=1.934, 95% confidence interval (CI): 1.055–3.579, P=0.033] and overall survival (HR=2.174, 95% CI: 1.102–4.290, P=0.025), independently of sex, age, growth pattern, differentiation and RT. In addition, FBI-1 was positively correlated with numerous biological factors, including p73 [Spearman's correlation coefficient (r
s )=0.332, P=0.007], lysyl oxidase (rs =0.234, P=0.043), Wrap53 (rs =−0.425, P=0.0002) and peroxisome proliferator-activated receptor δ (rs =−0.294, P=0.026). In conclusion, the present study demonstrated that nuclear FBI-1 was an independent prognostic factor in patients with RC and correlated with numerous biological factors, which indicated that it may have multiple roles in RC. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
16. Survival benefit of statins in older patients with rectal cancer: A Swedish population-based cohort study.
- Author
-
Kotti, Angeliki, Holmqvist, Annica, Albertsson, Maria, and Sun, Xiao-Feng
- Abstract
Increasing evidence suggests that statins may have antitumor effects but their role in rectal cancer appears inconclusive. The aim of this study was to investigate whether statins may have an impact on survival of older and younger patients with rectal cancer. This study included 238 patients ≥70 years and 227 patients <70 years old, from the Southeast Health Care Region of Sweden, who were diagnosed with rectal adenocarcinoma between 2004 and 2013. In the older group (n = 238), statin use at the time of diagnosis was related to better cancer-specific survival (CSS) and overall survival (OS), compared to non-use (CSS: Hazard Ratio (HR), 0.37; 95% CI, 0.19–0.72; P =.003; OS: HR, 0.62; 95% CI, 0.39–0.96; P =.032). In the older group with stages I-III disease (n = 199), statin use was associated with better disease-free survival (DFS) compared to non use (HR, 0.18; 95% CI, 0.06–0.59; P =.005). The improvement of CSS, OS and DFS remained significant after adjusting for potential confounders. In the older group with stage III disease, statin users had better CSS and DFS compared to non-users (log rank P =.043; log-rank P =.028, respectively). In the older group with short course radiotherapy, statin use was related to better CSS (log-rank P =.032). No such association was present in the younger group. Statin use was related to improved survival in older patients with rectal cancer. This observation is important given the low cost and safety of statins as a drug. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
17. Artificial intelligence–based 5‐year survival prediction and prognosis of DNp73 expression in rectal cancer patients.
- Author
-
Pham, Tuan D., Fan, Chuanwen, Zhang, Hong, and Sun, Xiao‐Feng
- Subjects
RECTAL cancer ,FORECASTING ,CANCER patients ,BREAST cancer prognosis ,CANCER prognosis ,PROGNOSIS ,CONVOLUTIONAL neural networks - Published
- 2020
- Full Text
- View/download PDF
18. Tafazzin Protein Expression Is Associated with Tumorigenesis and Radiation Response in Rectal Cancer: A Study of Swedish Clinical Trial on Preoperative Radiotherapy.
- Author
-
Pathak, Surajit, Meng, Wen-Jian, Zhang, Hong, Gnosa, Sebastian, Nandy, Suman Kumar, Adell, Gunnar, Holmlund, Birgitta, and Sun, Xiao-Feng
- Subjects
GENE expression ,RECTAL cancer ,CANCER radiotherapy ,CLINICAL trials ,NEOPLASTIC cell transformation ,MEMBRANE proteins ,CARDIOLIPIN - Abstract
Background: Tafazzin (TAZ), a transmembrane protein contributes in mitochondrial structural and functional modifications through cardiolipin remodeling. TAZ mutations are associated with several diseases, but studies on the role of TAZ protein in carcinogenesis and radiotherapy (RT) response is lacking. Therefore we investigated the TAZ expression in rectal cancer, and its correlation with RT, clinicopathological and biological variables in the patients participating in a clinical trial of preoperative RT. Methods: 140 rectal cancer patients were included in this study, of which 65 received RT before surgery and the rest underwent surgery alone. TAZ expression was determined by immunohistochemistry in primary cancer, distant, adjacent normal mucosa and lymph node metastasis. In-silico protein-protein interaction analysis was performed to study the predictive functional interaction of TAZ with other oncoproteins. Results: TAZ showed stronger expression in primary cancer and lymph node metastasis compared to distant or adjacent normal mucosa in both non-RT and RT patients. Strong TAZ expression was significantly higher in stages I-III and non-mucinious cancer of non-RT patients. In RT patients, strong TAZ expression in biopsy was related to distant recurrence, independent of gender, age, stages and grade (p = 0.043, HR, 6.160, 95% CI, 1.063–35.704). In silico protein-protein interaction study demonstrated that TAZ was positively related to oncoproteins, Livin, MAC30 and FXYD-3. Conclusions: Strong expression of TAZ protein seems to be related to rectal cancer development and RT response, it can be a predictive biomarker of distant recurrence in patients with preoperative RT. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
19. Livin expression is an independent factor in rectal cancer patients with or without preoperative radiotherapy.
- Author
-
Zhen-Yu Ding, Hong Zhang, Adell, Gunnar, Olsson, Birgit, Xiao-Feng Sun, Ding, Zhen-Yu, Zhang, Hong, and Sun, Xiao-Feng
- Subjects
RECTAL cancer patients ,RADIOTHERAPY ,IMMUNOGLOBULINS ,CANCER cells ,CELL lines - Abstract
Background: This study was aimed to investigate the expression significance of Livin in relation to radiotherapy (RT), clinicopathological and biological factors of rectal cancer patients.Methods: This study included 144 primary rectal cancer patients who participated in a Swedish clinical trial of preoperative radiotherapy. Tissue microarray samples from the excised primary rectal cancers, normal mucosa and lymph node metastases were immunostained with Livin antibody. The proliferation of colon cancer cell lines SW620 and RKO was assayed after Livin knock-down.Results: The expression of Livin was significantly increased from adjacent (P = 0.051) or distant (P = 0.028) normal mucosa to primary tumors. 15.4% (2/13) and 39.7% (52/131) patients with Livin-negative and positive tumors died at 180 months after surgery, and the difference tended to be statistically significant (P = 0.091). In multivariate analyses, the difference achieved statistical significance, independent of TNM stage, local and distant recurrence, grade of differentiation, gender, and age (odds ratio = 5.09, 95% CI: 1.01-25.64, P = 0.048). The in vitro study indicated colon cancer cells with Livin knock-down exhibited decreased proliferation compared with controls after RT.Conclusions: The expression of Livin was was independently related to survival in rectal cancer patients, suggesting Livin as a useful prognostic factor for rectal cancer patients. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
20. Downregulation of microRNA-124 is an independent prognostic factor in patients with colorectal cancer.
- Author
-
Wang, Mo-Jin, Li, Yuan, Wang, Rui, Wang, Cun, Yu, Yong-Yang, Yang, Lie, Zhang, Yi, Zhou, Bin, Zhou, Zong-Guang, and Sun, Xiao-Feng
- Subjects
TUMORS ,COLON cancer ,RECTAL cancer ,CELL differentiation ,CANCER research - Abstract
Purpose: Recently, microRNA-124 (miR-124) has been demonstrated as a potential tumor suppressor in several types of cancers. However, the role of miR-124 in colorectal cancer remains unclear. This study was aimed at investigating the clinicopathological significance of miR-124 expression in colorectal cancer. Methods: Quantitative real-time PCR was used to analyze miR-124 expression in 96 colorectal cancers and individual-matched normal mucosa samples. The expression of miR-124 was assessed for associations with clinicopathological characteristics using chi-square test. The survival curves were calculated by the Kaplan-Meier method. The influence of each variable on survival was examined by the Cox multivariate regression analysis. Results: The miR-124 expression was significantly downregulated in colorectal cancer compared to normal mucosa ( P = 0.001). In colorectal cancer, miR-124 decreased expression correlated significantly with the grade of differentiation ( P = 0.021). Univariate survival analysis showed that the downregulated miR-124 was significantly correlated with worse prognosis, both in terms of overall survival ( P = 0.017) and disease-free survival (DFS) ( P = 0.014). Further, the downregulated miR-124 was demonstrated as a prognostic factor for overall survival (hazard ratio, HR = 4.634; 95 % confidence interval, CI, 1.731-12.404; P = 0.002) and DFS (HR = 4.533, 95 % CI 1.733-11.856, P = 0.002), independently of gender, age, location, maximum tumor size, depth of invasion, differentiation, and TNM stage. Conclusions: MiR-124 may play a certain role in the development of colorectal cancer. The downregulation expression of miR-124 is an independent prognostic factor in patients with colorectal cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
21. Correlation of SATB1 overexpression with the progression of human rectal cancer.
- Author
-
Meng, Wen-Jian, Yan, Hui, Zhou, Bin, Zhang, Wei, Kong, Xiang-Heng, Wang, Rong, Zhan, Lan, Li, Yuan, Zhou, Zong-Guang, and Sun, Xiao-Feng
- Subjects
GENE expression ,RECTAL cancer ,NUCLEOTIDE sequence ,CARRIER proteins ,DISEASE progression ,POLYMERASE chain reaction ,IMMUNOHISTOCHEMISTRY - Abstract
Background and aims: To date, the association between special AT-rich sequence-binding protein 1 (SATB1) and colorectal cancer (CRC) has not been reported. This study was aimed at investigating the expression and potential role of SATB1 in human rectal cancers. Methods: Ninety-three paired samples of rectal cancer and distant normal rectal tissue were analyzed by quantitative real-time PCR (qRT-PCR) and immunohistochemistry (IHC), and the correlations between SATB1 expression and clinicopathological parameters were evaluated. The expression profiles of SATB1 were also investigated in a panel of five human colon carcinoma cell lines. Results: The general level of SATB1 mRNA in rectal cancer tissues was statistically significantly higher than that in normal mucosa ( P = 0.043). The rate of positive SATB1 protein expression in rectal cancers (44.1%) was significantly higher than that in normal tissues (25.8%) by IHC analysis ( P = 0.009). Overexpression of SATB1 mRNA was more predominant in patients with earlier onset of rectal cancer ( P = 0.033). SATB1 expression correlated with invasive depth and tumor node metastasis (TNM) stage at both protein and mRNA levels ( P < 0.05). Furthermore, SATB1 expression in the poorly metastatic KM12C cells was significantly lower than the highly metastatic KM12SM and KM12L4A cells and higher than the HCT116 and SW480 cells ( P = 0.001). These results were further confirmed by Western blotting. Conclusion: Our results indicate that SATB1 may play an important role in the progression of human rectal cancer, which represents a possible new mechanism underlying CRC. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
22. Microsatellite Instability Did Not Predict Individual Survival in Sporadic Stage II and III Rectal Cancer Patients.
- Author
-
Meng, Wen-Jian, Sun, Xiao-Feng, Chao Tian, Ling Wang, Yu, Yong-Yang, Zhou, Bing, Gu, Jun, Xia, Qing-Jie, Li, Yuan, Rong Wang, Zheng, Xue-Lian, and Zhou, Zong-Guang
- Subjects
- *
MICROSATELLITE repeats , *NUCLEOTIDE sequence , *PROGNOSIS , *RECTAL cancer , *TUMORS , *CARCINOEMBRYONIC antigen - Abstract
Objectives: Tumors with high-frequency microsatellite instability (MSI-H) have unique biological behavior and the predictive role of microsatellite instability (MSI) status on survival of colorectal cancer is still debated. The prognostic significance of MSI status in sporadic stage II and III rectal cancer patients needs to be more precisely defined. So we investigated the relationship between MSI status and clinicopathological features and prognosis in these patients. Methods: DNAs from fresh-frozen paired samples of tumors and corresponding normal tissue from 128 stage II and III rectal cancer patients were analyzed for MSI by PCR amplification using markers recommended by a National Cancer Institute workshop on MSI. To assess prognostic significance, Cox proportional hazards modeling was used. Results: Twelve (9.3%) tumors in our study were MSI-H, 28 (21.9%) were low-frequency MSI (MSI-L) and 88 (68.8%) were microsatellite stable (MSS). Most of the MSI-H tumors compared with MSI-L and MSS tumors were found in female patients (p = 0.031), had mucinous histology (p = 0.023), high grade of differentiation (p = 0.002) and high level of preoperative serum carcinoembryonic antigen (p = 0.005). Rectal cancer patients with MSI-H did not show a better clinical outcome than those with MSI-L/MSS, neither in all cases (p = 0.986) nor in stage II and stage III disease analyzed separately (p = 0.705 and p = 0.664, respectively). Conclusions: Data provided here demonstrated there was high incidence of MSI-H and MSI was not a prognostic factor in sporadic stage II and III rectal cancers from the Chinese Han population included in this study. Tumor stage is more suitable than MSI status for prediction of individual survival in sporadic stage II and III rectal cancer patients. Copyright © 2007 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
23. Survivin expression is an independent prognostic factor in rectal cancer patients with and without preoperative radiotherapy
- Author
-
Knutsen, Annica, Adell, Gunnar, and Sun, Xiao-Feng
- Subjects
- *
CANCER treatment , *PHOTOTHERAPY , *SURGERY , *TUMORS - Abstract
Purpose: Survivin, as an inhibitor of apoptosis, is undetectable in normal tissues but expressed in tumors. Survivin expression in rectal cancer patients who have undergone preoperative radiotherapy (RT) alone has not been studied. We analyzed the relationships of survivin expression to RT, clinicopathologic variables, apoptosis, and p53 expression in rectal cancer patients who participated in a trial of preoperative RT.Methods and materials: Survivin was immunohistochemically examined in 98 rectal tumors (74 had adjacent normal mucosa). Of 98 patients, 57 underwent surgery alone and 41 underwent RT before surgery.Results: Survivin positivity was related to worse survival, independent of Dukes'' stage, local and distant recurrence, differentiation, gender, age, apoptosis, and p53 expression (p = 0.02). Survivin was not associated with survival in the patients without (p = 0.08) or with (p = 0.19) RT. After RT, survivin tended to be increased in adjacent normal mucosa (p = 0.057) but not in tumors (p = 0.71).Conclusion: Survivin was independently related to survival in rectal cancer patients who participated in a trial of preoperative RT, but not in either treatment group (surgery alone or surgery plus RT). Whether the effect of survivin on tumors is associated with RT and further related to patient survival needs to be investigated in a larger number of patients. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
24. The Critical Role of Dysregulated RhoB Signaling Pathway in Radioresistance of Colorectal Cancer.
- Author
-
Liu, Na, Cui, Weiyingqi, Jiang, Xia, Zhang, Zhiyong, Gnosa, Sebastian, Ali, Zaheer, Jensen, Lasse, Jönsson, Jan-Ingvar, Blockhuys, Stéphanie, Lam, Eric W.-F., Zhao, Zengren, Ping, Jie, Xie, Ning, Kopsida, Maria, Wang, Xin, and Sun, Xiao-Feng
- Subjects
- *
COLORECTAL cancer , *RECTAL cancer , *CANCER cells , *CELL lines , *RADIOTHERAPY - Abstract
Purpose: To explore whether the Rho protein is involved in the radioresistance of colorectal cancer and investigate the underlying mechanisms.Methods and Materials: Rho GTPase expression was measured after radiation treatment in colon cancer cells. RhoB knockout cell lines were established using the CRISPR/Cas9 system. In vitro assays and zebrafish embryos were used for analyzing radiosensitivity and invasive ability. Mass cytometry was used to detect RhoB downstream signaling factors. RhoB and Forkhead box M1 (FOXM1) expression were detected by immunohistochemistry in rectal cancer patients who participated in a radiation therapy trial.Results: RhoB expression was related to radiation resistance. Complete depletion of the RhoB protein increased radiosensitivity and impaired radiation-enhanced metastatic potential in vitro and in zebrafish models. Probing signaling using mass cytometry-based single-cell analysis showed that the Akt phosphorylation level was inhibited by RhoB depletion after radiation. FOXM1 was downregulated in RhoB knockout cells, and the inhibition of FOXM1 led to lower survival rates and attenuated migration and invasion abilities of the cells after radiation. In the patients who underwent radiation therapy, RhoB overexpression was related to high FOXM1, late Tumor, Node, Metastasis stage, high distant recurrence, and poor survival independent of other clinical factors.Conclusions: RhoB plays a critical role in radioresistance of colorectal cancer through Akt and FOXM1 pathways. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
25. SPARCL1 Expression Increases With Preoperative Radiation Therapy and Predicts Better Survival in Rectal Cancer Patients.
- Author
-
Kotti, Angeliki, Holmqvist, Annica, Albertsson, Maria, and Sun, Xiao-Feng
- Subjects
- *
RECTAL cancer patients , *RECTAL cancer treatment , *CANCER radiotherapy , *CYSTEINE , *RECTAL cancer , *IMMUNOHISTOCHEMISTRY , *PROGNOSIS - Abstract
Purpose: The secreted protein acidic and rich in cysteine-like 1 (SPARCL1) is expressed in various normal tissues and many types of cancers. The function of SPARCL1 and its relationship to a patient's prognosis have been studied, whereas its relationship to radiation therapy (RT) is not known. Our aim was to investigate the expression of SPARCL1 in rectal cancer patients who participated in a clinical trial of preoperative RT. Methods and Materials: The study included 136 rectal cancer patients who were randomized to undergo preoperative RT and surgery (n=63) or surgery alone (n=73). The expression levels of SPARCL1 in normal mucosa (n=29), primary tumor (n=136), and lymph node metastasis (n=35) were determined by immunohistochemistry. Results: Tumors with RT had stronger SPARCL1 expression than tumors without RT (P=.003). In the RT group, strong SPARCL1 expression was related to better survival than weak expression in patients with stage III tumors, independent of sex, age, differentiation, and margin status (P=.022; RR = 18.128; 95% confidence interval, 1.512-217.413). No such relationship was found in the non-RT group (P=.224). Further analysis of interactions among SPARCL1 expression, RT, and survival showed statistical significance (P=.024). In patients with metastases who received RT, strong SPARCL1 expression was related to better survival compared to weak expression (P=.041) but not in the non-RT group (P=.569). Conclusions: SPARCL1 expression increases with RT and is related to better prognosis in rectal cancer patients with RT but not in patients without RT. This result may help us to select the patients best suited for preoperative RT. [Copyright &y& Elsevier]
- Published
- 2014
- Full Text
- View/download PDF
26. Expression of FXYD-3 is an Independent Prognostic Factor in Rectal Cancer Patients With Preoperative Radiotherapy
- Author
-
Loftås, Per, Önnesjö, Sofia, Widegren, Emma, Adell, Gunnar, Kayed, Hany, Kleeff, Jörg, Zentgraf, Hanswalter, and Sun, Xiao-Feng
- Subjects
- *
GENE expression , *RECTAL cancer , *CANCER patients , *CANCER radiotherapy , *CLINICAL trials , *IMMUNOHISTOCHEMISTRY , *ONCOLOGIC surgery , *CANCER prognosis , *PROGNOSIS - Abstract
Purpose: FXYD-3 (MAT-8) is overexpressed in several types of cancers; however, its clinical relevance in rectal cancers has not been studied. Therefore, we examined FXYD-3 expression in rectal cancers from the patients who participated in a Swedish clinical trial of preoperative radiotherapy (RT) to determine whether FXYD-3 was overexpressed in rectal cancers and correlated with RT, survival, and other clinicopathologic variables. Methods and Materials: The study included 140 rectal cancer patients who participated in a clinical trial of preoperative RT, 65 with and 75 without RT before surgery. FXYD-3 expression was immunohistochemically examined in distant (n = 70) and adjacent (n = 101) normal mucosa, primary tumors (n = 140), and lymph node metastasis (n = 36). Results: In the whole cohort, strong FXYD-3 expression was correlated with infiltrative tumor growth (p = 0.02). In the RT group, strong FXYD-3 expression alone (p = 0 .02) or combined with phosphatase of regenerating liver was associated with an unfavorable prognosis (p = 0.02), independent of both TNM stage and tumor differentiation. In tumors with strong FXYD-3 expression, there was less tumor necrosis (p = 0.02) and a trend toward increased incidence of distant metastasis (p = 0.08) after RT. None of these effects was seen in the non-RT group. FXYD-3 expression in the primary tumors tended to be increased compared with normal mucosa regardless of RT. Conclusion: FXYD-3 expression was a prognostic factor independent of tumor stage and differentiation in patients receiving preoperative RT for rectal cancer. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
27. Significance of an exon 2 G4C14-to-A4T14 polymorphism in the p73 gene on survival in rectal cancer patients with or without preoperative radiotherapy
- Author
-
Lööf, Jasmine, Pfeifer, Daniella, Adell, Gunnar, and Sun, Xiao-Feng
- Subjects
- *
EXONS (Genetics) , *GENETIC polymorphisms , *SURVIVAL analysis (Biometry) , *RECTAL cancer patients , *PREOPERATIVE care , *CANCER radiotherapy , *CANCER genetics , *HEALTH outcome assessment - Abstract
Abstract: Background and purpose: An exon 2 G4C14→A4T14 polymorphism in the p73 gene was shown to be related to survival in several types of cancers, including colorectal cancer. The purpose was to investigate if this polymorphism was related to survival in rectal cancer patients with or without preoperative radiotherapy. Materials and methods: DNA extracted from tissue of 138 rectal cancer patients that received preoperative radiotherapy or had surgery alone was typed for the polymorphism by PCR using confronting two-pair primers. Results: Among patients, 69% had GC/GC genotype, 27% had GC/AT and 4% had AT/AT. In the radiotherapy group, patients carrying the AT (GC/AT+AT/AT) allele had stronger expression of p53 (p =0.001) and survivin protein (p =0.03) than those carrying the GC/GC genotype. Further, among patients receiving preoperative radiotherapy the GC/GC genotype tended to be related to better survival (p =0.20). Patients with GC/GC genotype, along with negative p53 and weak survivin expression showed better survival than the other patients (p =0.03), even after adjusting for TNM stage and tumor differentiation (p =0.01, RR, 7.63, 95% CI, 1.50–38.74). In the non-radiotherapy group, the polymorphism was not related to survival (p =0.74). Conclusions: Results suggest that the p73 G4C14→A4T14 polymorphism could be one factor influencing outcome of preoperative radiotherapy in rectal cancer patients. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
28. Expression of the p73 protein in rectal cancers with or without preoperative radiotherapy
- Author
-
Pfeifer, Daniella, Gao, Jingfang, Adell, Gunnar, and Sun, Xiao-Feng
- Subjects
- *
RADIOTHERAPY , *TUMORS , *MUCOUS membranes , *IMMUNOHISTOCHEMISTRY , *CHI-squared test , *CLINICAL trials , *COMPARATIVE studies , *INTESTINAL mucosa , *RESEARCH methodology , *MEDICAL cooperation , *MEMBRANE proteins , *METASTASIS , *ONCOGENES , *OXIDOREDUCTASES , *PROTEINS , *RESEARCH , *DNA-binding proteins , *EVALUATION research , *PROPORTIONAL hazards models , *NUCLEAR proteins ,RECTUM tumors - Abstract
Purpose: To investigate p73 expression in normal mucosa, primary tumor, and metastasis in relation to radiotherapy (RT) response and clinicopathologic/biologic variables in rectal cancers.Methods and Materials: p73 was immunohistochemically examined on biopsies (unirradiated, n=102), distant (from the large bowel, n=82), and adjacent (adjacent to primary tumor, n=89) normal mucosa samples, primary tumors (n=131), and lymph node metastasis (n=32) from rectal cancer patients participating in a clinical trial of preoperative RT. Seventy-four patients received surgery alone and 57 received additional RT.Results: Cytoplasmic p73 was increased in the primary tumor compared with the distant or adjacent mucosa (pConclusions: Normal epithelial cells seem more sensitive to RT than tumor cells regarding p73 expression. Patients with p73-negative rectal tumors may have a lower risk of local recurrence after RT. [ABSTRACT FROM AUTHOR] - Published
- 2006
- Full Text
- View/download PDF
29. Expression of PRL proteins at invasive margin of rectal cancers in relation to preoperative radiotherapy
- Author
-
Wallin, Åsa R., Svanvik, Joar, Adell, Gunnar, and Sun, Xiao-Feng
- Subjects
- *
PHOSPHATASES , *LIVER regeneration , *REGENERATION (Biology) , *METASTASIS , *COLON cancer , *RADIOTHERAPY - Abstract
Purpose: PRL-3 (phosphatase of regenerating liver) is involved in metastasis of colorectal cancer; however, its therapeutic implication in cancer patients has not been studied. We investigated the relationships of PRL expression to radiotherapy (RT) in rectal cancer patients. Methods and Materials: Phosphatase of regenerating liver expression was immunohistochemically examined in distant (n = 36) and adjacent (n = 82) normal mucosa, primary tumor (n = 125), biopsy specimens (n = 96), and lymph node metastasis (n = 30) from rectal cancer patients participating in a clinical trial of preoperative RT. Results: Phosphatase of regenerating liver expression was increased from the distant to adjacent mucosa and to the primary tumor (p < 0.05). PRL was highly expressed at the invasive margin in 28% of the primary tumors and 26% of the metastases. In the RT group, strong PRL expression at the invasive margin was related to distant recurrence (p = 0.006) and poor survival (p = 0.01), but not in the non-RT group. The survival significance remained even after adjusting for Dukes’ stage and differentiation (p = 0.02). Additional multivariate analyses showed that the correlation with prognostic significance of PRL differed between the RT and non-RT groups (p = 0.01). Conclusion: Phosphatase of regenerating liver expression (rather than PRL-3 alone) at the invasive margin predicted resistance to RT and unfavorable survival in rectal cancer patients with preoperative RT. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
30. Significance of Cox-2 expression in rectal cancers with or without preoperative radiotherapy
- Author
-
Pachkoria, Ketevan, Zhang, Hong, Adell, Gunnar, Jarlsfelt, Ingvar, and Sun, Xiao-Feng
- Subjects
- *
RECTAL cancer , *CANCER patients , *RADIOTHERAPY , *IMMUNOHISTOCHEMISTRY - Abstract
Purpose: Radiotherapy has reduced local recurrence of rectal cancers, but the result is not satisfactory. Further biologic factors are needed to identify patients for more effective radiotherapy. Our aims were to investigate the relationship of cyclooxygenase-2 (Cox-2) expression to radiotherapy, and clinicopathologic/biologic variables in rectal cancers with or without radiotherapy. Methods and Materials: Cox-2 expression was immunohistochemically examined in distal normal mucosa (n = 28), in adjacent normal mucosa (n = 107), in primary cancer (n = 138), lymph node metastasis (n = 30), and biopsy (n = 85). The patients participated in a rectal cancer trial of preoperative radiotherapy. Results: Cox-2 expression was increased in primary tumor compared with normal mucosa (p < 0.0001), but there was no significant change between primary tumor and metastasis. Cox-2 positivity was or tended to be related to more p53 and Ki-67 expression, and less apoptosis (p ≤ 0.05). In Cox-2–negative cases of either biopsy (p = 0.01) or surgical samples (p = 0.02), radiotherapy was related to less frequency of local recurrence, but this was not the case in Cox-2–positive cases. Conclusion: Cox-2 expression seemed to be an early event involved in rectal cancer development. Radiotherapy might reduce a rate of local recurrence in the patients with Cox-2 weakly stained tumors, but not in those with Cox-2 strongly stained tumors. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.